Functional Links between the Immune System, Brain Function and Behavior (R21) | Apply Online

FAQs: Functional Links between the Immune System, Brain Function and Behavior (R21) - NIH PA 08-098

What is the name of this NIH grant opportunity?

The funding opportunity is titled Functional Links between the Immune System, Brain Function and Behavior (R21), and it is identified as NIH PA 08-098.

What is the main purpose of PA 08-098?

This opportunity is intended to support early-stage, exploratory studies that investigate how the immune system and the central nervous system (CNS) communicate, with an emphasis on neuroimmune molecules and mechanisms.

What kinds of scientific topics does this FOA emphasize?

The FOA emphasizes "neuroimmune" molecules and mechanisms, including the signals, cells, pathways, and interactions that lie at the intersection of immunology and neuroscience. The goal is to improve understanding of how immune-related processes regulate normal brain function and how disruptions may contribute to CNS dysfunction, changes in behavior, and neurological or psychiatric disease states.

What is meant by "neuroimmune" mechanisms in this announcement?

In this context, "neuroimmune" refers to the biological signals, immune and neural cells, pathways, and cross-system interactions through which immune processes influence the brain and behavior (and potentially how brain processes relate to immune signaling).

What NIH activity code or mechanism does this program use?

This opportunity uses the NIH R21 mechanism, which is designed for exploratory or developmental research.

What types of projects are a good fit for an R21 under this FOA?

The R21 is positioned for projects that are promising but not yet fully developed, potentially high risk/high reward, or efforts that need initial proof-of-concept data before a larger, more definitive project is feasible.

Is there an R01 version of this same scientific topic?

Yes. The FOA notes it runs in parallel with an R01 version of the same topic: PA 08-097. The R01 is described as better suited for more mature, hypothesis-driven projects with substantial preliminary data.

Is there also an R03 option referenced for smaller projects?

Yes. The FOA references an R03 mechanism for small research grants: PA 06-180, which can support more limited-scope efforts.

Why does this opportunity involve multiple NIH Institutes and Centers?

The announcement is sponsored by multiple NIH Institutes and Centers, signaling that neuroimmune communication is considered cross-cutting across disciplines and disease areas. The participating components reflect relevance to mental health, aging, substance use, neurological disorders, cancer-related symptoms or treatment effects, and technology development for studying human health.

Which NIH Institutes and Centers are listed as participating?

Participating components include: the National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute on Neurological Disorders and Stroke (NINDS), and the National Cancer Institute (NCI).

How much funding can an R21 project request under this listing?

The listing includes an award ceiling of $200,000, consistent with the general expectation that R21 projects are smaller and more time-limited than R01s.

Does the FOA guarantee a certain number of awards or a fixed total budget?

No. The announcement does not commit to a fixed number of awards or a single standardized budget. NIH indicates the actual number of awards, total dollars, and project periods depend on the number of applications received, scientific quality, proposed duration, and requested costs.

What factors determine the number of awards and the funding levels?

According to the information provided, NIH bases award decisions on factors such as the volume of applications, their scientific quality, proposed project duration, and requested costs.

Who is eligible to apply for this grant opportunity?

Eligibility is broad and includes many organization types, including nonprofit organizations (both 501(c)(3) and non-501(c)(3)), for-profit organizations (including small businesses), public and private institutions of higher education, and various government entities (state, county, city/township, special district governments, and independent school districts). Public housing authorities and tribal organizations are also included, including federally recognized tribal governments.

Are small businesses eligible to apply?

Yes. The eligibility description includes small businesses among eligible applicants.

Are for-profit organizations eligible to apply?

Yes. The eligibility description includes for-profit organizations (other than small businesses) as well as small businesses.

Can universities and colleges apply?

Yes. Both public and private institutions of higher education are listed as eligible applicants.

Can state, local, or special district governments apply?

Yes. Eligible government applicants include state governments, county governments, city/township governments, special district governments, and independent school districts.

Are tribal organizations eligible?

Yes. The FOA includes tribal organizations, including federally recognized tribal governments, among eligible applicants.

Are foreign institutions allowed to apply?

Yes. The FOA explicitly states that foreign institutions may apply.

Can federal agencies apply?

Yes. The FOA clarifies that eligible federal agencies may apply.

Are faith-based or community-based organizations eligible?

Yes. The FOA states that faith-based or community-based organizations may apply.

Is cost sharing or matching required?

No. The FOA explicitly states there is no cost sharing or matching requirement, meaning applicants are not required to contribute their own funds as a condition of the award.

What type of grant is this considered?

This is described as a discretionary grant opportunity from the National Institutes of Health (NIH).

Which broad funding activity categories are associated with this opportunity?

The opportunity is categorized under education and health-related funding activity.

What CFDA program areas are associated with this opportunity?

The opportunity is associated with multiple CFDA program areas that mirror the participating NIH components and the breadth of the topic, including areas such as mental health, aging, drug abuse, neuroscience/neurological disorders, cancer control, arthritis and musculoskeletal/skin diseases, and biomedical imaging and bioengineering, among others.

When was this announcement posted?

The announcement record indicates it was posted on March 4, 2008.

Is this funding opportunity still open?

Based on the dates provided, it appears to be no longer active. The record shows a current closing date of January 7, 2010 and an archive date of February 7, 2010.

What dates are listed for closing and archiving?

The record shows an original closing date of May 16, 2011, a current closing date of January 7, 2010, and an archive date of February 7, 2010.

How should applicants decide between the R21 and the parallel R01?

Based on the description provided, the R21 is meant for exploratory, developmental, or proof-of-concept work (often higher risk and earlier stage), while the parallel R01 (PA 08-097) is described as better suited for more mature, hypothesis-driven projects with substantial preliminary data.

What is the overall goal of the research encouraged by this FOA?

The overall aim is to advance understanding of how immune signaling shapes brain function and behavior, and how disruptions in immune-brain pathways may drive or worsen CNS-related diseases, with the expectation that early R21 findings could later grow into larger-scale studies under mechanisms such as the R01.